



**HAL**  
open science

## CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation

E. Martin, N. Palmic, S. Sanquer, C. Lenoir, F. Hauck, C. Mongellaz, S. Fabrega, P. Nitschke, M. D. Esposti, J. Schwartzentruber, et al.

► **To cite this version:**

E. Martin, N. Palmic, S. Sanquer, C. Lenoir, F. Hauck, et al.. CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. *Nature*, 2014, 510 (7504), pp.288–92. 10.1038/nature13386 . hal-02191580

**HAL Id: hal-02191580**

**<https://hal.science/hal-02191580v1>**

Submitted on 28 Sep 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Published in final edited form as:

*Nature*. 2014 June 12; 510(7504): 288–292. doi:10.1038/nature13386.

## CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation

**Emmanuel Martin<sup>1,2</sup>, Noé Palmic<sup>1,2</sup>, Sylvia Sanquer<sup>3</sup>, Christelle Lenoir<sup>1,2</sup>, Fabian Hauck<sup>1,2</sup>, Cédric Mongellaz<sup>4</sup>, Sylvie Fabrega<sup>2,5</sup>, Patrick Nitschké<sup>2,6</sup>, Mauro Degli Esposti<sup>7,8</sup>, Jeremy Schwartzentruber<sup>9</sup>, Naomi Taylor<sup>4</sup>, Jacek Majewski<sup>9</sup>, Nada Jabado<sup>9,10</sup>, Robert Wynn<sup>7</sup>, Capucine Picard<sup>2,11,12</sup>, Alain Fischer<sup>1,2,13,14</sup>, Peter Arkwright<sup>7,\*</sup>, and Sylvain Latour<sup>1,2,3,\*</sup>**

<sup>1</sup>Laboratoire Activation Lymphocytaire et Susceptibilité à l'EBV, INSERM UMR 1163, Hôpital Necker Enfants-Malades, Paris, France

<sup>2</sup>Université Paris Descartes Sorbonne Paris Cité, Institut Imagine, Paris, France

<sup>3</sup>Laboratoire de Biochimie Métabolomique et Protéomique, Hôpital Necker Enfants-Malades, Paris, France

<sup>4</sup>Institut de Génétique Moléculaire, Montpellier, France

<sup>5</sup>Plateforme Vecteurs Viraux et Transfert de Gènes, IFR94, Hôpital Necker Enfants-Malades, Paris, France

<sup>6</sup>Service de Bioinformatique, Hôpital Necker Enfants-Malades, Paris, France

<sup>7</sup>University of Manchester, Manchester, United Kingdom

<sup>8</sup>Italian Institute of Technology, Genoa, Italy

<sup>9</sup>McGill University and Genome Québec Innovation Centre, Montréal, Canada

<sup>10</sup>Department of Pediatrics, McGill University Health Center Research Institute, Montréal, Canada

<sup>11</sup>Centre d'Etude des Déficiences Immunitaires, Hôpital Necker Enfants-Malades, AP-HP, Paris, France

<sup>12</sup>Laboratoire Génétique Humaine des Maladies Infectieuses, INSERM UMR 1163, Hôpital Necker Enfants-Malades, Paris, France

<sup>13</sup>Unité d'Immunologie et Hématologie Pédiatrique, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Paris, France

---

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:[http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

Correspondence and requests for materials should be addressed to: Sylvain Latour, Laboratory of Lymphocyte Activation and Susceptibility to EBV, INSERM UMR 1163, Imagine Institute, 24 boulevard du Montparnasse, Paris 75015 Cedex, France; [sylvain.latour@inserm.fr](mailto:sylvain.latour@inserm.fr); Tel: 33 1 01 42 75 43 03; FAX: 33 1 42 75 42 21.

**Author contributions** E.M. performed experiments, analyzed the data and participated in the writing of the manuscript. N.P., F.H., C.L., S.F., C.A., C.M., S.S. performed experiments. A.F., S.L., S.S., J.S., C.P., P.N., J.M., N.J., C.M. and N.T. analyzed the data. M.D.E., R.W. and P.A., identified the families, provided and analyzed clinical information. S.L. and A.F. co-wrote the manuscript. S.L. designed and supervised the research.

\*joint senior authorship

The authors declare no competing financial interests.

<sup>14</sup>Collège de France, Paris, France

## Abstract

Lymphocyte functions triggered by antigen recognition and cosignals imply rapid and intense cell division, hence metabolism adaptation<sup>1</sup>. The cytidine nucleotide triphosphate (CTP) is a precursor required for the metabolism of DNA, RNA and phospholipids<sup>2-4</sup>. CTP originates from two sources: a salvage pathway and a *de novo* synthesis pathway that depends on two enzymes, the CTP synthase (or synthetase) 1 and 2 (CTPS1 and CTPS2), although their respective roles are not known<sup>5-7</sup>. CTP synthase activity is a potentially important step for DNA synthesis in lymphocytes<sup>8,9</sup>. Here, we report the identification of a loss of function homozygous mutation (rs145092287) in *CTPS1* in humans causing a novel and life threatening immunodeficiency characterized by an impaired capacity of activated T and B cells to proliferate in response to antigen receptor-mediated activation. In contrast, proximal and distal TCR signaling events and responses were only weakly affected by the absence of CTPS1. Activated CTPS1-deficient cells exhibited decreased levels of CTP. Normal T-cell proliferation was restored in CTPS1-deficient cells by expressing wild-type *CTPS1* or by addition of exogenous CTP or its nucleoside precursor, cytidine. CTPS1 expression was found to be low in resting T cells, but rapidly upregulated following TCR activation. These results highlight a key and specific role of CTPS1 in the immune system by its capacity to sustain the proliferation of activated lymphocytes during the immune response. CTPS1 may therefore represent a therapeutic target of immunosuppressive drugs that could specifically dampen lymphocyte activation.

---

We initially studied two unrelated families (family 1 and 2) originating from the northwest region of England, whose four children suffered from severe and recurrent Epstein-Barr virus (EBV) infection, in whom known primary immunodeficiencies have been excluded<sup>10</sup> (Fig. 1a and Table 1). Four additional patients (family 3 to 5) originating from the same geographical area were identified thereafter (Methods). All patients had early onset of severe chronic viral infections, mostly caused by herpes viruses, including EBV and Varicella Zooster Virus (VZV) and, also suffered from recurrent encapsulated bacterial infections, a spectrum of infections typical of a combined deficiency of adaptive immunity (CID)<sup>11</sup> (Table 1 and data not shown). Overall, the clinical phenotype is severe with 3 patients have died. Six of 8 patients have undergone hematopoietic stem cell transplantation. Of note, none of the patients had extra-hematopoietic manifestations (Table 1).

Immunological investigations showed that most of patients had variable lymphopenia which was exacerbated during infection episodes with inversed CD4:CD8 T-cell ratio, while other blood cell counts were usually normal (Extended Data Table 1 and data not shown). Their immunoglobulin levels were normal or elevated with increased IgG but low IgG2 levels with low antibody titers to *Streptococcus pneumoniae*. Further analyses were performed in patient P1.2 showing naive CD4<sup>+</sup> T-cell lymphopenia, increased numbers of effector memory T cells, low numbers of memory CD27<sup>+</sup> B cells, a complete absence of both invariant T cell populations (CD3<sup>+</sup>V $\alpha$ 24<sup>+</sup>V $\beta$ 11<sup>+</sup>) iNKT and (CD3<sup>+</sup>CD161<sup>high</sup>V $\alpha$ 7.2<sup>+</sup>) MAIT cells, as well as an impaired PHA- and antigen-induced proliferation of peripheral blood mononuclear cells (PBMCs) (Extended Data Table 2).

To identify the gene defect underlying the immunodeficiency in these patients, we performed whole exome sequencing (WES) in three patients (P1.1, P1.2 and P2.1). Intersection of the genetic variations found in the three patients pointed to a unique common homozygous G to C mutation in the *CTPS1* gene encoding the CTP synthase 1 at position 41475832 in chromosome 1 with an assigned rsID (rs145092287) in the dbSNP database (Fig. 1b and Extended Data Fig. 1a,b). *CTPS1* encodes a 67-kDa protein containing a CTP synthetase domain and a glutamine amide transfer domain promoting the formation of CTP from UTP and glutamine<sup>12</sup>. The identified mutation affects a splice donor site at the junction of intron 17-18 and exon 18 (IVS18-1 G>C) leading to the expression of an abnormal transcript lacking exon 18 (Extended Data Fig. 1b,c). This splice mutation was found to be deleterious since CTPS1 protein expression could not be detected in lysates of EBV-transformed B cells and T-cell blasts from patients (Fig. 1c, Fig. 2c and Extended Data Fig. 2). In contrast, CTPS2 was expressed normally in patient cell lysates. In the five affected families, all patients were homozygous for the IVS18-1 G>C mutation and all parents and tested healthy siblings were heterozygous carriers (Fig. 1a,b and data not shown). Sequencing of a cohort of 752 healthy individuals from the northwest of England gave an estimated frequency of homozygosity of 1:560,000. This represents more than a 10-fold increase compared to the frequency estimated from available exome databases. WES data and analysis of polymorphic microsatellite markers in all patients revealed a common region of homozygosity of 1.1 Mb surrounding the IVS18-1 G>C mutation (Supplementary information). All these data were indicative of a founder effect. These observations led us to conclude that the immunodeficiency resulting from the *CTPS1* mutation in these patients could be primarily associated with a T-cell immunodeficiency.

We next examined CTPS1 expression in normal tissues. CTPS1 mRNA expression was comparable between the different tissues, except for T cells in which CTPS1 expression was strongly up regulated after cell activation in response to TCR-CD3 and CD28 co-stimulation (Fig. 1d). Interestingly, in lysates from T-cell blasts and T cells from PBMCs, CTPS1 protein was almost undetectable (Fig. 2a-d). In contrast, CTPS2 expression was readily detected. Activation of T cells by anti-CD3 antibody or phorbol 12-myristate 13-acetate (PMA) and ionomycin stimulations induced CTPS1 protein expression while activation with IL-2 and/or IL-15 resulted in only weak effect. Under the same experimental conditions, CTPS2 expression was also induced but to a lesser extent. In TCR-CD3-stimulated T-cell blasts, CTPS1 protein expression was enhanced from 12 hours and persisted for up to 96 hours as a consequence of *CTPS1* gene transcription activation (Fig. 1d, inset and Fig. 2b). As expected, no expression of CTPS1 was detected in T-cell blasts from the CTPS1-deficient patient (P1.2) contrasting with detection of CTPS1 mRNA and suggesting protein instability (Fig. 2c and Extended Data Fig. 1c). These data indicate that T-cell activation through the TCR results in a rapid and sustained CTPS1 protein expression. Of note, in B cells activated by anti-BCR and CpG, IL-4 and CD40L or PMA and ionomycin, CTPS1 was also found to be upregulated (Fig. 2d and Extended Data Fig. 3a,b).

To further characterize the consequences of the CTPS1 deficiency in T cells, we investigated proximal T-cell activation signals as well as late responses. CTPS1-deficient T cells exhibited normal early and late responses with the exception of ERK1/2 phosphorylation and CD25 and CD69 upregulation which were found to be decreased (Extended Data Fig.

4). Basal and activation-induced cell death was also slightly increased (Extended Data Fig. 4g). These data suggest that CTPS1 deficiency had limited consequences in signaling downstream of TCR-CD3. Because the pool of CTP is potentially a limiting factor for DNA synthesis<sup>8, 13</sup>, we carefully analyzed proliferation of CTPS1-deficient T-cells. In response to activation by antigens, anti-CD3 antibody or co-stimulation by anti-CD3 and anti-CD28 antibodies, CTPS1-deficient cells from three patients (P1.1, P1.2 and P2.2) failed to sustain proliferative responses as measured by <sup>3</sup>H-thymidine uptake and CFSE or violet cell tracer dye dilution (resulting in a weak index of cell proliferation) (Fig. 2e,f and Extended Data Table 1 and Extended Data Fig. 5, 6). Uptakes of <sup>3</sup>H-Uridine and <sup>3</sup>H-Cytidine were also found to be impaired in activated CTPS1-deficient T cells. This suggests that both RNA and DNA synthesis were affected (Extended Data Fig. 6). Defective proliferation of CTPS1-deficient T cells was associated with a lack of cell cycle progression since a majority of cells were arrested in the G1 phase (Fig. 2g). Proliferation of CTPS1-deficient B cells activated by anti-BCR and CpG was also found to be defective whereas that of IL-2-activated NK cells seemed to be less affected (Fig. 2h and Extended Data Fig. 5b).

Down-regulation of CTPS1 expression in control T cells, by lentiviral transduction of two distinct shRNA together with a GFP reporter gene, led to a specific decrease in the CD3-mediated proliferation of GFP-positive cells (Fig. 3a). No changes in proliferation were detected in non-targeted GFP-negative cells or in cells targeted with a scramble shRNA. The diminished proliferation resulting from the inhibition of CTPS1 expression led to a selective cell growth disadvantage with a decreased number of GFP targeted cells over time (middle panel). A similar decrease in proliferation rate was also observed in the Jurkat T-cell line in which CTPS1 expression was down-regulated (Extended Data Fig. 7).

Together, these results indicate that CTPS1 deficiency causes a defect in T-cell proliferation in response to TCR-CD3 activation. To formally prove the causal relationship between CTPS1 deficiency and defective T-cell proliferation, we carried out reconstitution experiments with wild-type *CTPS1* or by direct addition of CTP or its cytidine precursor that acts on CTP levels via the salvage pathway. Expression of ectopic CTPS1 in CTPS1-deficient T-cells fully restored proliferation upon CD3 stimulation (Fig. 3b) and enabled cells to expand selectively as shown by the accumulation of GFP-positive cells expressing CTPS1 (Fig. 3c, left panels). No such effect was detected in CTPS1-deficient cells transduced with an empty vector or in control cells transduced with the CTPS1-containing vector.

Proliferation and CD25 expression of CTPS1-deficient cells also recovered to a normal level by addition of CTP or cytidine (Fig. 3d and data not shown). In contrast, addition of a mix of UTP, GTP and ATP or uracil, guanine and adenosine did not result in increased proliferation of CTPS1-deficient cells. To determine the influence of the CTPS1 defect on the *de novo* pyrimidine synthesis pathway, we measured the incorporation of carbon from <sup>14</sup>C-aspartate into nucleic acids of activated CTPS1-deficient T cells, which is a specific assay for *de novo* pyrimidine synthesis<sup>14</sup> (Fig. 3e and Extended Data Fig. 6 b,c). Incorporation of <sup>3</sup>H-thymidine and <sup>3</sup>H-uridine was analyzed in parallel as control of the global RNA and DNA synthesis. TCR-CD3 activation-mediated incorporation of <sup>14</sup>C-aspartate, <sup>3</sup>H-thymidine and <sup>3</sup>H-uridine was significantly decreased in CTPS1-deficient T cells. Addition of exogenous

CTP or cytidine that bypassed the *de novo* synthesis pathway restored incorporation of  $^3\text{H}$ -thymidine but not of  $^{14}\text{C}$ -aspartate in CTPS1-deficient cells, thus demonstrating that the *de novo* CTP synthesis pathway is impaired in the absence of CTPS1. Deazauridine, an analogue of UTP and a known inhibitor of CTP synthetase activity<sup>15</sup> completely blocked T-cell proliferation of control cells in response to CD3 activation without affecting proximal TCR-CD3-mediated responses, similar to results observed in CTPS1-deficient cells (Fig. 3f and data not shown). As expected, inhibition of T-cell proliferation by deazauridine was fully reverted by addition of CTP and partially by UTP, but not by ATP or GTP. Analysis of nucleotides pools in activated CTPS1-deficient T-cell blasts and CTPS1-deficient B/EBV cell lines revealed decreased levels of CTP, as also observed in activated normal cells treated with deazauridine (Fig. 3g,h). Defective CTPS1 expression or addition of deazauridine also led to reduced pools of ATP, GTP and UTP in activated T cells (Extended Data Fig. 8) suggesting interconnection in the nucleotide pools<sup>16</sup>. In contrast, CTP as well as ATP, GTP and UTP were found to be normal or increased in resting CTPS1-deficient T cells as the salvage pathway is predominant in quiescent cells<sup>17</sup>. Expression of wild-type CTPS1 in CTPS1-deficient B/EBV cell lines restored levels of CTP comparable to control cells and conferred to cells a selective cell growth advantage (Fig. 3h,i).

This study reveals a critical role for CTPS1 in promoting the proliferation of T cells following their activation. However, proliferation of B cells was also found to be dependent of CTPS1. This may directly participate to the susceptibility to encapsulated bacterial infections seen in CTPS1-deficient patients and account for the low titers of *S. pneumoniae* antibodies as it is a T-independent B-cell response. The role of CTPS1 in B cells could be different or/and less important than in T cells. Of note, CTPS1-deficient B cells preserve an intact capacity to expand upon transformation by EBV and patients had normal Ig levels and/or elevated IgG. Decreased expansion of NK cells and low numbers of iNKT and MAIT cells might also contribute to the CTPS1 immunodeficiency as these cells have been proposed to play a role in a broad range of immune responses including anti-EBV immunity<sup>18-21</sup>. The finding that CTPS1-deficiency causes no other significant clinical consequences favors a redundancy with CTPS2 activity in other cell lineages and tissues. Interestingly, pyrimidine pools including CTP have been previously shown to be strongly expanded in PHA-stimulated T cells via *de novo* pathways including increased CTPS activity<sup>8, 9</sup>. The induction of CTPS1 expression in activated T cells reported here thus appears as the major determinant of CTP pool increase. Indeed, proliferation of CTPS1-deficient T cells was restored to normal level by addition of CTP. The exact mechanism(s) by which TCR signaling induces a rapid expression and activation of CTPS1 in T cells remains to be determined, although we showed that the ERK pathway is required as well as tyrosine phosphorylation signals (Extended data Fig. 3c). It is interesting to note that T cell differentiation does not appear to be severely impaired by CTPS1 deficiency, suggesting that CTP pools in thymocytes may originate from the nucleoside salvage pathway and/or the CTPS2 activity<sup>8, 22-24</sup>. Notably though, CTPS1 activity is critical for the intense cell division induced by antigenic stimulation as exemplified by massive proliferation and expansion of CD8<sup>+</sup> T cells during viral infections<sup>25, 26</sup>.

In the absence of CTPS1, we showed that *de novo* pyrimidine synthesis pathway is impaired but not totally abrogated. This residual activity is likely dependent of CTPS2. Recently, the

*de novo* pyrimidine synthesis pathway was shown to be dependent on post-transcriptional regulation by mTORC1 and S6 protein (S6K) kinases that activate the first enzymatic steps required for pyrimidine synthesis<sup>14, 27, 28</sup>. Thus, distinct regulatory mechanisms control *de novo* pyrimidine synthesis. Based on the present study, CTPS1-mediated tuning of CTP synthesis in lymphocytes appears to be a key element in enabling adaptive immune responses. If CTPS1-specific inhibitors can be designed, they would potentially be highly specific immunosuppressive drugs able to inhibit auto- or allogenic-specific T and B cell responses without additional toxicity given the lymphocyte specificity of the CTPS1-deficiency phenotype. In conclusion, our results provide the first *in vivo* evidence of a role of the *de novo* pyrimidine synthesis pathway as a critical step for proliferation of T and B lymphocytes when activated by antigens.

## METHODS

### Cohorts of patients

Beside the four initially identified patients, four additional patients were identified by screening 10 patients (9 families) originating from the northwest of England with severe chronic viral infections, mostly caused by herpes viruses, including EBV and VZV. Furthermore, 24 patients (24 families) originating from different geographical areas with the same phenotype were also tested for all exons of *CTPS1* in order to identify other mutations and none was found to be a carrier of CTPS1 mutations.

### Exome sequencing and analysis

Exome capture was performed according to the manufacturer's protocol using the Illumina TruSeq exome enrichment kit and sequencing of 100 bp paired end reads on an Illumina HiSeq. Approximately 10 Gb of sequence were obtained for each subject such that 90% of the coding bases of the exome defined by the consensus coding sequence (CCDS) project were covered by at least 10 reads. Adaptor sequences and quality trimmed reads were removed using the Fastx toolkit ([http://hannonlab.cshl.edu/fastx\\_toolkit/](http://hannonlab.cshl.edu/fastx_toolkit/)) and a custom script was then used to ensure that only read pairs with both mates present were subsequently used. Reads were aligned to hg19 with BWA31, and duplicate reads were marked using Picard (<http://picard.sourceforge.net/>) and excluded from downstream analyses. Single nucleotide variants (SNVs) and short insertions and deletions (indels) were determined using samtools (<http://samtools.sourceforge.net/>) pileup and varFilter32 with the base alignment quality (BAQ) adjustment disabled, and they were then quality filtered to require at least 20% of reads supporting the variant call. Variants were annotated using both ANNOVAR33 and custom scripts to identify whether they affected protein coding sequences, and whether they had previously been seen in the dbSNP, the 1000 Genomes data set (1092 genomes), or in approximately 2073 exomes previously sequenced at our center. A variant detected in a patient was considered to be a candidate mutation if it had not been reported or had a frequency below 0.001% in the three databases indicated above. At the time the homozygous G>C mutation in *CTPS1* (at position chr1:41475832) was identified by WES in the three patients (P1.1, P1.2 and P2.1), it was not described as a dbSNP or assigned to a rsID. Since, this mutation has been identified in the NHLBI GO Exome Sequencing Project (<http://evs.gs.washington.edu/EVS/>) with the assigned rsID:

rs145092287. In the NHLBI GO Exome Sequencing Project, the rs145092287 is present three times in a heterozygous status among 4300 genomes from an European-American population and not found in the 2203 genomes of an African-American population. The rs145092287 was not found in an homozygous or heterozygous status in other available genome databases (NCBI, 1000 Genomes project and the 3519 genomes of our center). Homozygosity regions around the rs145092287 were determined in the exomes by looking at the homozygous variations. Between the positions chr1:40737516 (rs6677717) and chr1:42008077 (rs 63729761) a succession of 97 homozygous variations (without heterozygous variations) was found to be shared by the three patients.

### Genomic DNA sequencing

Genomic DNA from peripheral blood cells, EBV-B cell lines and/or fibroblasts of patients, their parents, and other family members was isolated according to standard methods. Genomic DNAs of 752 healthy control subjects born in the North West of England were obtained from the UK 1958 Birth Cohort (<http://www2.le.ac.uk/projects/birthcohort/1958BC-About>). The estimated frequency of the *CTPS1* mutation in the populations was calculated according to the Hardy-Weinberg law. Oligonucleotide primers flanking the 3' region of intron 17-18 and exon 18 of *CTPS1* were used to amplify genomic DNA: Forward 5'-AGAGTTGGTGGTAGGGTGTGTGAC-3' and reverse 5'-CTTGCAATCGCAGTGTGTTATCAC-3'. PCR products were amplified using high fidelity Platinum Taq DNA Polymerase (Invitrogen) according to the manufacturer's recommendations, purified with the QIAquick gel extraction kit (Qiagen) and sequenced using the ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit (PerkinElmer) according to the manufacturer's recommendations. All collected sequences were analysed using 4peaks software (Version 1.7.2; A. Griekspoor and T. Groothuis, <http://nucleobytes.com/index.php/4peaks>).

### Analysis of microsatellite markers

Microsatellite markers were genotyped using UniSTS sequences and mapping information available from the NCBI (<http://www.ncbi.nlm.nih.gov>). Genomic DNA from patients was used as templates to amplify by PCR with specific fluorescent labelled oligonucleotides, the polymorphic repeats corresponding to the microsatellite markers. PCR products were evaluated using an ABI 3100 DNA Fragment Analyzer (Applied Biosystems), and data were analyzed using Genescan and Genotyper software (Applied Biosystems).

### Gene expression analysis

Total RNA was isolated from EBV-B cell and activated T cell blasts of P1.2, P2.1 patients and control donors using the RNeasy Mini kit (QIAGEN). The samples were depleted of genomic DNA and reverse transcription was performed using Superscript II First Strand Synthesis System (Invitrogen). cDNAs were used as a template to perform PCR amplifications of exon 15 to exon 19 of *CTPS1* or exon 4 of *ACTIN* with the following primers using standard protocols: *CTPS1* forward primer: 5'-GAGAGGCACCGCCACCGATTTG-3', *CTPS1* reverse primer: 5'-GCCAGTACACGTGATGGGACATGC-3', *ACTIN* forward primer: 5'-CTCCTTAATGTACGCACGAT-3'; *ACTIN* reverse primer: 5'-



CTCCTTAATGTCACGCACGAT-3'. PCR to amplify full length *CTPS1* cDNAs from control and patients cells were also performed using the following primers: forward primer: 5'-AGCTCTGCTCGCTGACGGGAGGAT-3' (exon1); reverse primer: 5'-GCCAGTACACGTGATGGGACATGC-3' (exon 19). PCR products were verified by sequencing revealing the expression of an abnormal *CTPS1* transcript lacking exon 18 in patients cells. Multiple tissue cDNA panels from Ozyme (Human MTC panel I, II and Human Immune System MTC panel) were analyzed for *CTPS1* and *CTPS2* gene expression by RT-qPCR. Gene expression assays were performed with Assays-on-Demand probe and primer combinations (*CTPS1*, Hs01041858; *CTPS2*, Hs00219845; *GAPDH*, Hs027558991) from Applied Biosystem labeled with 6-carboxy-fluorescein (FAM) dye, and universal reaction mixture. Real time quantitative PCRs for *GAPDH*, *CTPS1* and *CTPS2* were performed in triplicate using a LightCycler VIIA7 System (Roche). Expression levels were determined by relative quantification using the comparative threshold cycle method  $2^{-Ct}$  in which  $Ct$  is determined as followed:  $(Ct_{\text{target gene}} - Ct_{\text{reference gene}})_{\text{target tissue}} - (Ct_{\text{target gene}} - Ct_{\text{reference gene}})_{\text{calibrator tissue}}$ . The results shown in arbitrary units (A.U.) have been normalized to *GAPDH* gene expression and are presented as the relative change in gene expression normalized against the calibrator sample corresponding to leukocyte tissue.

### Cell culture and stimulation

Peripheral blood mononuclear cells (PBMCs) collected from patients and healthy donors were isolated by Ficoll-Paque density gradient (Lymphoprep, Proteogenix) from blood samples using standard procedures. Expansion of T-cell blasts were obtained by incubating PBMCs for 72 h with phytohaemagglutinin (PHA) ( $2.5 \mu\text{g ml}^{-1}$ , Sigma-Aldrich) in RPMI 1640 GlutaMax medium (Invitrogen) supplemented with 5% human AB serum (Etablissement Français du Sang), penicillin ( $100 \text{ U ml}^{-1}$ ) and streptomycin ( $100 \mu\text{g ml}^{-1}$ ). After 3 days, dead cells were removed by Ficoll-Paque density gradient and blasts were maintained in culture with IL-2 ( $100 \text{ UI ml}^{-1}$ ). For proliferation and cell cycle analyses, blasts were washed and cultured without IL-2 for 72 hours to synchronize the cells. Blasts or PBMCs were then cultured during 4 to 6 days in complete medium alone or in the presence of 0.1, 1 or  $10 \mu\text{g ml}^{-1}$  coated anti-CD3 antibody (clone OKT3, eBiosciences), anti-CD3/CD28-coated beads (Invitrogen), PHA ( $2.5 \mu\text{g ml}^{-1}$ ,  $10^{-5} \text{ M}$  ionomycin (Sigma-Aldrich) plus  $10^{-7} \text{ M}$  Phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich), Candidin ( $5 \mu\text{g ml}^{-1}$ , Bio-Rad), tetanus toxoid (1/8000 dilution, Statens Serum Institute) or tuberculosis antigen ( $50 \mu\text{g ml}^{-1}$ , Statens Serum Institute). Proliferation and cell cycle were analysed at the indicated time points.  $40 \mu\text{M}$  of 3-Deazauridine (DAZ, Sigma-Aldrich) was added for 12 hours before the stimulation. In complementation experiments, blasts were incubated with  $100 \mu\text{M}$  of CTP, UTP, GTP or ATP (New England Biolabs) separately or in combination, or with  $200 \mu\text{M}$  of Cytidine, Uridine, Guanosine or Adenosine (Sigma-Aldrich) separately or in combination 12 hours before the stimulation. For dosage of nucleotides, blasts were deprived of IL-2 for 72 hours before stimulation or not with anti-CD3/CD28-coated beads for 48 h and cell lysates were prepared. Jurkat cells<sup>29</sup>, 293-T cells and B EBV cell lines from patients were cultured in RPMI 1640 GlutaMax medium supplemented with 10 % heat-inactivated fetal calf serum (GIBCO), penicillin ( $100 \text{ U ml}^{-1}$ ) and streptomycin ( $100 \mu\text{g ml}^{-1}$ ). Cells were free of mycoplasma contamination.

### Proliferation and cell cycle assays

Cell proliferation was monitored by labelling cells with the cell trace violet dye (CellTrace violet proliferation kit, Invitrogen) or CFSE (5 $\mu$ M, Invitrogen) prior to stimulation, according to the manufacturer's instructions. After 4 or 6 days of culture, cells were harvested and CellTrace violet or CFSE fluorescence dilution was assessed by flow cytometry. The division index of proliferation was calculated using Flowjo software (Tree Star) and corresponds to the average number of cell divisions per cell including the undivided peak. T-cell responses within total PBMCs were also measured by [<sup>3</sup>H]-thymidine incorporation after 6 days of stimulation. 0.074 MBq ml<sup>-1</sup> of [<sup>3</sup>H]-thymidine was added during the last 18 h of stimulation. Cell proliferation was determined by cpm of [<sup>3</sup>H] thymidine incorporated in cells that were counted with TopCount NXT beta counter (PerkinElmer). Cell cycle analysis was determined by measuring the incorporation of the nucleoside analogue 5-ethynyl-2-deoxyuridine (EdU) into newly synthesized DNA, according to the manufacturer's instructions (Click-iT EdU, Invitrogen) after 48 h of anti-CD3 stimulation. EdU incorporation in cells was measured following conjugation of EdU to azide-modified Alexa Fluor 647 dye. Cells were analyzed by flow cytometry with a FACS-Canto II flow cytometry system (BD Biosciences).

### Nucleic acids and de novo pyrimidine synthesis assays

PBMCs were stimulated in the presence of 1  $\mu$ g ml<sup>-1</sup> coated anti-CD3 antibody (clone OKT3, eBiosciences) or 2.5  $\mu$ g ml<sup>-1</sup> PHA (Sigma-Aldrich) for 3 days or in the presence of candidin (5  $\mu$ g ml<sup>-1</sup>, Bio-Rad), tetanus toxoid (1/8000 dilution, Statens Serum Institute) or PPD (tuberculin) (50  $\mu$ g ml<sup>-1</sup>, Statens Serum Institute) for 6 days. 0.074 MBq ml<sup>-1</sup> of [<sup>3</sup>H]-thymidine, [<sup>3</sup>H]-cytidine, [<sup>3</sup>H]-uridine or [<sup>3</sup>H]-leucine or 0.185 MBq ml<sup>-1</sup> U-[<sup>14</sup>C]-aspartate were added during the last 18 h of stimulation. For [<sup>3</sup>H]-cytidine, this corresponds to 0.133  $\mu$ M, which not allows to restore normal proliferation of CTPS1-deficient cells that required 50 $\mu$ M. Cells were harvested with a Filter Mate harvester (PerkinElmer) on filters for labelled cell assays (Unifilter™ plates, PerkinElmer) that retain nucleic acids and filters were then washed. Radioactivity (cpm) on filters (corresponding to radiolabelled compounds incorporated in nucleic acids) was measured by liquid scintillation counting with TopCount NXT beta counter (PerkinElmer).

### Apoptosis assay

Apoptosis was determined by evaluating phosphatidylserine (PS) exposure in the outer leaflet of the cytoplasmic membrane with PE-conjugated Annexin-V in combination with 7-AAD Viaprobe (Apoptosis Detection Kit I, BD) 12 hours after stimulation with coated-OKT3 (0.1, 1 or 10  $\mu$ g ml<sup>-1</sup>). Apoptosis was based on the percentage of Annexin V<sup>+</sup>/7AAD<sup>-</sup> cells to exclude necrotic cells. Cells were analyzed by flow cytometry.

### Cytokine production and degranulation

For intracellular staining of cytokines, cells were stimulated overnight with PMA and ionomycin or anti CD3/CD28 beads in the presence of brefeldin A (GolgiPlug, BD). Cells were then fixed and permeabilized using the BD cytofix/cytoperm plus kit (BD Pharmingen) according to the manufacturer's instructions. Cells were labelled with PE-anti-IL-2 (rat

IgG2a, MHQ1-17H12), PE/Cy7-anti-TNF- $\alpha$  (mouse IgG1; MAb11), APC-anti-IFN- $\gamma$  (mouse IgG1, 4S.B3) and isotype-matched mAbs purchased from Biolegend and analysed by flow cytometry. Degranulation was determined by analysis of the expression of CD107/LAMP, a marker of the exocytosis of lytic granules. Blasts were stimulated for 3 hours in the presence of 0.3, 3 or 30  $\mu\text{g ml}^{-1}$  coated-OKT3 and simultaneously labelled with eFluor660-anti-CD107a (mouse IgG1; eBioH4A3), eFluor660-anti-CD107b (mouse IgG1; eBioABL-93) or isotype matched mAbs purchased from eBiosciences. Thereafter, cells were harvested, washed and stained with FITC-anti-CD3 and PE-anti-CD8 mAbs and analyzed by flow cytometry.

### Flow cytometry

Cell staining and the flow-cytometry-based phenotypic analyses of PBMCs and cells were performed according to standard flow cytometry methods. The following mAbs were conjugated to fluorescein isothiocyanate (FITC), phycoerythrin (PE), phycoerythrin-Cyanine7 (PE/Cy7), phycoerythrin-Cyanine5, phycoerythrin-Cyanine5.5, allophycocyanin (APC), allophycocyanin-Vio7, View blue or View green: anti-CD25 (M-A251), anti-CD27 (M-T271), anti-CD31 (WM59), anti-CD45RA (HI100), anti-CD45RO (UCHL1), anti-CD197/CCR7 (3D12), anti-TCR $\alpha\beta$  (T10B9), anti-TCR $\gamma\delta$ (B1), anti-CD95 (DX2), anti-CD19 (HIB19), anti-CD21 (B-ly4), anti-IgM (G20-127), anti-IgD (IA6-2), anti-CD56 (B159) and anti-CD16 (3G8), all purchased from BD Biosciences and anti-CD3 (BW264/56), anti-CD4 (VIT4), anti-CD8 (BW135/80) and anti-CD69 (FN50) from Miltenyi Biotec. iNKT cells were detected by staining with anti-V $\alpha$ 24 (C15) and anti-V $\beta$ 11 (C21) (Beckman Coulter) and MAIT cells by staining with anti-V $\alpha$ 7.2 (3C10) and anti-CD161 (HP-3G10 (Biolegend). All data were collected on a FACS-Canto II cytometer (BD Biosciences) and analysed using FlowJo Version 9.3.2 software (TreeStar).

### Immunoblotting and analysis CTPS1 protein expression

Cells ( $5 \times 10^6$  cells/ml) were stimulated by anti-CD3 antibody ( $1 \mu\text{g ml}^{-1}$ ) cross-linking with a rabbit-anti-mouse IgG ( $2 \mu\text{g ml}^{-1}$ ) or anti CD3/CD28 beads for the indicated time periods. Cells were then lysed in 1% NP40, 50 mM Tris pH 8, 150 mM NaCl, 20 mM EDTA, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 mM NaF and complete protease inhibitor cocktail (Roche), as previously described<sup>30</sup>. Protein concentrations were quantitated by BCA assay (BIO-RAD). 80  $\mu\text{g}$  of proteins were separated by SDS-PAGE and transferred on PVDF membranes (Millipore). Membranes were blocked with milk or BSA before incubation with antibodies. The following mAbs and rabbit polyclonal antibodies were used for immunoblotting: anti-PLC- $\gamma$ 1 (#2822S), anti-phosphorylated PLC- $\gamma$ 1 (#2821S), anti-phosphorylated ERK1/2 (clone E10, #9106S), anti-ERK1/2 (#4695S) anti-phosphorylated I $\kappa$ B—clone 5A5, #9246S), anti-phosphorylated PKC $\theta$  (#9377S), NF $\kappa$ B (clone D14E12) anti-phosphorylated AKT (Serine 473, clone 587F11) and anti-phosphorylated tyrosine (4G10) purchased from Cell Signaling Technology and rabbit polyclonal antibodies anti-ACTIN (#A2066) and anti-CTPS1 raised against the residues 341 to 355 (#SAB111071) or 416-430 (#SAB111072) and anti-CTPS2 (#HPA017437) purchased from Sigma Aldrich. Anti-CTPS1 rabbit polyclonal antibodies (K-21) from Santa Cruz were also tested. Membranes were then washed and incubated with anti-mouse or anti-rabbit HRP-conjugated secondary antibodies from Cell Signaling and GE Healthcare, respectively. Pierce ECL western blotting substrate

was used for detection. For inhibition assays of the signaling pathways after TCR-CD3 activation, cells have been stimulated with anti-CD3/CD28 beads for 48 h in the presence of 100 nM of the MAPK/ERK inhibitor PD0325901, 10 $\mu$ M of the Src family protein tyrosine kinase inhibitor PP1, 10 $\mu$ M of the Src family protein tyrosine kinase inhibitor PP2, 10 $\mu$ M of the selective Ca<sup>2+</sup> chelator 1,2-bis-(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl) ester (BAPTA/AM), 10 $\mu$ M of the I $\kappa$ B $\alpha$  phosphorylation inhibitor Bay 11-7085 or 10 $\mu$ M of PI3Kdelta inhibitor IC87114. All were from Sigma-Aldrich, excepted IC87114 from Calbiochem. The concentrations used were typical and previously reported. After 48 h incubation with the different inhibitors, cell viability was verified and was more than 90% in each condition. The activity and the selectivity of the inhibitors was verified in parallel by immunoblotting for phospho-tyrosine (for PP1 and PP2), I $\kappa$ B $\alpha$  phosphorylation (for Bay 11-7085), ERK phosphorylation (for PD0325901) and AKT phosphorylation (for IC87114) (data not shown).

### Calcium flux analysis

Ca<sup>2+</sup> responses were assessed by flow cytometry, as previously described<sup>31</sup>. Briefly, cells were loaded with 5  $\mu$ M Indo-1 AM (Molecular Probes), washed, incubated with anti-CD4-APC and anti-CD8-PE mAbs, stimulated by anti-CD3 antibody (0.125  $\mu$ g ml<sup>-1</sup>) cross-linking with F(ab')<sub>2</sub> rabbit-anti-mouse IgG (10  $\mu$ g ml<sup>-1</sup>) and then incubated with ionomycin (1  $\mu$ M). Cells were analyzed with a FACS ARIA flow cytometer (BD Biosciences). Ca<sup>2+</sup> flux data were obtained using kinetic analyses of FlowJo software package (TreeStar). Intracellular Ca<sup>2+</sup> levels correspond to the normalized ratio of Ca<sup>2+</sup>-bound to Ca<sup>2+</sup>-free Indo-1 fluorescence and are plotted as a function of time.

### Plasmid constructs, cell transfections and infections

A full length cDNA encoding wild-type CTPS1 and a full length cDNA encoding the mutant CTPS1delta18 were obtained by RT-PCR from control blasts and blasts from patient 1.2 respectively using the forward 5'-CGGGATCCCACCATGAAGTATATTCTGGTT-3' and reverse 5'-CCGCTCGAGTCAGTCATGATTTAT TGA-3' (for wild-type) and 5'-CCGCTCGAGTTAAAGAAAGTCTCCAAGC-3' (for CTPS1delta18) specific primers. The cDNAs were verified by sequencing and inserted into a bicistronic lentiviral expression vector encoding the green fluorescent protein (GFP) as a reporter (pLenti7.3/V5-TOPO, Invitrogen). Viral particles for infection were obtained by coexpression of the lentiviral vector containing CTPS1 with third-generation lentiviral plasmids containing Gag-Pol, Rev and the G protein of the vesicular stomatitis virus (VSVG) into HEK 293T using calcium phosphate. Viral supernatants were collected every 12 h on 2 consecutive days, starting 48 h after transfection, and viral particles were concentrated by ultracentrifugation at 49,000 g for 1.5 h at 12°C. Cells were infected with viral particles at a minimal titer of 10<sup>7</sup> TU ml<sup>-1</sup> and 48 h after infection, cells were deprived of IL-2 during 72 h for proliferation assays. To assess the selective advantage of GFP expression during long-term expansion, blasts were re-stimulated with antiCD3/CD28 beads (Invitrogen) every 48 h during 8 days. For CTPS1 gene knockdown, blasts or Jurkat cells were infected at day 3 of PHA stimulation with the pLKO.1 lentiviral vector containing a CTPS1-specific shRNA (Openbiosystems, n°TRCN0000045349 and n°TRCN0000045350) or a scrambled shRNA in which the puromycin resistance gene was replaced by the GFP gene. Proliferation was analyzed in

GFP<sup>+</sup> and GFP<sup>-</sup> blasts after 4 days of stimulation with anti-CD3/CD28 beads as previously described. For survey of loss of GFP expression in long-term expansions, blasts were repeatedly stimulated with anti-CD3/CD28 beads every 48 h during 8 days. Jurkat cells were maintained in culture after infection during 26 days. The proportions percentages of GFP<sup>+</sup> cells were determined by flow cytometry.

### Quantification of intracellular nucleotides

Intracellular pools of nucleotides were quantified based on previously described methods<sup>32,33</sup>. Briefly, 5 millions of cells were washed in 0.1 M phosphate buffer (pH=7.4) and lysed in 60  $\mu$ L HClO<sub>4</sub> 1M, containing 2  $\mu$ M 8-bromo-AMP (8-BrAMP) as an internal standard. After 12,000 g centrifugation for 5 min at 4°C, supernatants were transferred to a 384-wells plate and kept at 4°C in auto sampler before injection. Aliquots of 5  $\mu$ L were injected onto a separation column (ACQUITY UPLC BEH300 C18, 1.7  $\mu$ m, 2.1 $\times$ 100 mm reversed-phase column, Waters) with a flow rate of 0.5 mL/min and analyzed with a tandem mass spectrometry system consisting of an Acquity Ultra Performance Liquid Chromatography (UPLC Waters) interfaced with a xevo-TQ-S tandem quadrupole mass spectrometer (Waters). Mobile phase A was 0.1% formic acid in water and mobile phase B, 0.1% formic acid in acetonitrile. A programmed mobile phase-gradient was used during a 7-min run: 0 min, 1% B; 5 min, 10% B; 5.1 min, 100% B; 6 min, 100% B; 6.1 min, 1% B; 7 min, 1% B. The content of the 4 nucleotides ATP, GTP, UTP and CTP was quantified in the electrospray negative ion mode with multiple reaction monitoring (MRM). Transitions of m/z 505.9>408 and 505.9>272.9 were used for quantification and confirmation of ATP, respectively, and those of 521.9>158.9 and 521.9>177 for GTP, 482.8>158.9 and 482.8>79 for UTP, and 481.8>158.9 and 481.8>384 for CTP. Concentrations were determined by using calibration curves of the 4 nucleotides. The linearity, exactitude and variability were determined for the technical validation of this assay. The linearity gave a correlation coefficient of the linear regression curves greater than 0.99 for the 4 nucleotides. The minimum and maximum recovery of spiked samples with the 4 nucleotides at a concentration of 90 mg/L and 250 mg/L ranged from 72% to 123%. The maximum intra- and inter-assay variability was of 22% and 23%, respectively.

### Statistical analysis

*P* values were calculated with the Students t-test using PRISM software (GraphPad Software), with a two-tailed distribution. The variance was similar between the groups that have been statistically compared.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgements


The authors thank the patients, their families and the healthy donors for cooperation. We thank S. Rigaud, S. Gérard, C. Synaeve and R. Rodriguez for help with experiments and P. Revy for discussion. This work was supported by grants from INSERM, ANR (ANR-08-MIEN-012-01, ANR-2010-MIDI-005-02 and ANR-10-LAHU-01), Fondation ARC (France), the European Research Council (ERC-2009-AdG\_20090506 n°FP7-249816) and the Rare Diseases Fondation (France). S. L. is a senior scientist of CNRS (France). E. M. is supported by ANR (France) and

Ligue contre le cancer (France). We are also grateful to the UK 1958 Birth Cohort (<http://www2.le.ac.uk/projects/birthcohort/1958BC-About>) for providing DNA from 752 individuals born in the North West of England. Access to these resources was enabled via the 58READIE Project funded by the Wellcome Trust and Medical Research Council (grant numbers WT095219MA and G1001799). A full list of the financial, institutional and personal contributions to the development of the 1958 Birth Cohort Biomedical resource is available at <http://www2.le.ac.uk/projects/birthcohort>.

## References


1. MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. *Annu Rev Immunol.* 2013; 31:259–83. [PubMed: 23298210]
2. Evans DR, Guy HI. Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. *J Biol Chem.* 2004; 279:33035–8. [PubMed: 15096496]
3. Higgins MJ, Graves PR, Graves LM. Regulation of human cytidine triphosphate synthetase 1 by glycogen synthase kinase 3. *J Biol Chem.* 2007; 282:29493–503. [PubMed: 17681942]
4. Ostrander DB, O'Brien DJ, Gorman JA, Carman GM. Effect of CTP synthetase regulation by CTP on phospholipid synthesis in *Saccharomyces cerevisiae*. *J Biol Chem.* 1998; 273:18992–9001. [PubMed: 9668079]
5. Kassel KM, Au da R, Higgins MJ, Hines M, Graves LM. Regulation of human cytidine triphosphate synthetase 2 by phosphorylation. *J Biol Chem.* 2010; 285:33727–36. [PubMed: 20739275]
6. Nadkarni AK, et al. Differential biochemical regulation of the URA7- and URA8-encoded CTP synthetases from *Saccharomyces cerevisiae*. *J Biol Chem.* 1995; 270:24982–8. [PubMed: 7559626]
7. van Kuilenburg AB, Meinsma R, Vreken P, Waterham HR, van Gennip AH. Identification of a cDNA encoding an isoform of human CTP synthetase. *Biochim Biophys Acta.* 2000; 1492:548–52. [PubMed: 10899599]
8. Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. *J Biol Chem.* 1995; 270:29682–9. [PubMed: 8530356]
9. van den Berg AA, et al. Cytidine triphosphate (CTP) synthetase activity during cell cycle progression in normal and malignant T-lymphocytic cells. *Eur J Cancer.* 1995; 31A:108–12. [PubMed: 7695960]
10. Wynn RF, et al. Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation. *Lancet Oncol.* 2005; 6:344–6. [PubMed: 15863383]
11. Notarangelo LD. Functional T cell immunodeficiencies (with T cells present). *Annu Rev Immunol.* 2013; 31:195–225. [PubMed: 23298211]
12. Kursula P, et al. Structure of the synthetase domain of human CTP synthetase, a target for anticancer therapy. *Acta Crystallogr Sect F Struct Biol Cryst Commun.* 2006; 62:613–7.
13. Traut TW. Physiological concentrations of purines and pyrimidines. *Mol Cell Biochem.* 1994; 140:1–22. [PubMed: 7877593]
14. Ben-Sahra I, Howell JJ, Asara JM, Manning BD. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. *Science.* 2013; 339:1323–8. [PubMed: 23429703]
15. McPartland RP, Wang MC, Bloch A, Weinfeld H. Cytidine 5'-triphosphate synthetase as a target for inhibition by the antitumor agent 3-deazauridine. *Cancer Res.* 1974; 34:3107–11. [PubMed: 4472653]
16. Qiu Y, et al. Mycophenolic acid-induced GTP depletion also affects ATP and pyrimidine synthesis in mitogen-stimulated primary human T-lymphocytes. *Transplantation.* 2000; 69:890–7. [PubMed: 10755546]
17. van den Berg AA, et al. The roles of uridine-cytidine kinase and CTP synthetase in the synthesis of CTP in malignant human T-lymphocytic cells. *Leukemia.* 1994; 8:1375–8. [PubMed: 8057676]
18. Le Bourhis L, Mburu YK, Lantz O. MAIT cells, surveyors of a new class of antigen: development and functions. *Curr Opin Immunol.* 2013; 25:174–80. [PubMed: 23422835]
19. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. *Nat Immunol.* 2008; 9:503–10. [PubMed: 18425107]

20. Chung BK, et al. Innate immune control of EBV-infected B cells by invariant natural killer T cells. *Blood*. 2013; 122:2600–8. [PubMed: 23974196]
21. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. *Nat Rev Immunol*. 2013; 13:101–17. [PubMed: 23334244]
22. Toy G, et al. Requirement for deoxycytidine kinase in T and B lymphocyte development. *Proc Natl Acad Sci U S A*. 107:5551–6.
23. Marijnen YM, et al. Studies on the incorporation of precursors into purine and pyrimidine nucleotides via ‘de novo’ and ‘salvage’ pathways in normal lymphocytes and lymphoblastic cell-line cells. *Biochim Biophys Acta*. 1989; 1012:148–55. [PubMed: 2787169]
24. Austin WR, et al. Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress. *J Exp Med*. 2012; 209:2215–28. [PubMed: 23148236]
25. Murali-Krishna K, et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. *Immunity*. 1998; 8:177–87. [PubMed: 9491999]
26. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. *Annu Rev Immunol*. 2007; 25:587–617. [PubMed: 17378764]
27. Huang M, Graves LM. De novo synthesis of pyrimidine nucleotides; emerging interfaces with signal transduction pathways. *Cell Mol Life Sci*. 2003; 60:321–36. [PubMed: 12678497]
28. Robitaille AM, et al. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. *Science*. 2013; 339:1320–3. [PubMed: 23429704]
29. Gülow K, Kaminski M, Darvas K, Süß D, Li-Weber M, Krammer PH. HIV-1 trans-activator of transcription substitutes for oxidative signaling in activation-induced T cell death. *J Immunol*. May 1; 2005 174(9):5249–60. [PubMed: 15843521]
30. Latour S, et al. Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. *Nat Immunol*. 2001; 2:681–90. [PubMed: 11477403]
31. Picard C, et al. Hypomorphic mutation of ZAP70 in human results in a late onset immunodeficiency and no autoimmunity. *Eur J Immunol*. 2009; 39:1966–76. [PubMed: 19548248]
32. Luo B, Groenke K, Takors R, Wandrey C, Oldiges M. Simultaneous determination of multiple intracellular metabolites in glycolysis, pentose phosphate pathway and tricarboxylic acid cycle by liquid chromatography-mass spectrometry. *J Chromatogr A*. 2007; 1147:153–64. [PubMed: 17376459]
33. Scavennec J, Maraninchi D, Gastaut JA, Carcassonne Y, Cailla HL. Purine and pyrimidine ribonucleoside monophosphate patterns of peripheral blood and bone marrow cells in human acute leukemias. *Cancer Res*. 1982; 42:1326–30. [PubMed: 6277481]



**Figure 1. Identification of *CTPS1* deficiency in patients with a combined immunodeficiency**  
**a**, Pedigrees of the families in which an homozygous IVS18-1 G>C mutation in *CTPS1* were identified. When known, the genotype of each individual is indicated. Black boxes represent affected individuals and diagonal bars indicate deceased individuals. Each patient (P) is identified by a number. **b**, Diagram of the *CTPS1* intron-exon organization and protein domains with the serine phosphorylation sites (S) indicated and the coding exons in grey. DNA electropherograms showing the region containing the mutation in *CTPS1* in family 1. The homozygous IVS18-1 G>C mutation is indicated by an arrow. **c**, Immunoblots for CTPS1 and CTPS2 expression in non stimulated EBV B-cell lines from healthy controls and CTPS1-mutated individuals (P1.1, P1.2 and P2.1). ACTIN serves as loading control. **d**, CTPS1 mRNA expression in normal tissues monitored by RT-qPCR in arbitrary units (A.U.). The inset shows the kinetic of CTPS1 mRNA expression following anti-CD3/CD28 beads stimulation.






**Figure 2. Induction of CTPS1 expression during T-cell activation and defective proliferation of activated CTPS1-deficient T-cells**

**a-d**, Immunoblots for CTPS1 and CTPS2 expression (**a**) in control T-cells (from a healthy donor) stimulated with various stimuli or (**b**) stimulated with anti-CD3 for different periods of time, (**c**) in control (Ctr.) or CTPS1-deficient cells from patient P1.2 stimulated with anti-CD3 for different periods of time and (**d**) in normal PBMCs sorted B- and T-cells stimulated with indicated stimuli. ACTIN serves as loading control. **e**, Representative dot plots showing cell divisions by dilution of the violet dye and expression of CD25 of control (Ctr.) or

CTPS1-deficient T-cells (patient P1.2) stimulated with incremental doses of the anti-CD3 antibody or anti-CD3/CD28 coated beads. Inserts with histograms showing the violet dye dilution with the number cell divisions indicated at the top of each peak. Representative data from one of 4 independent experiments. **f**, Mean of index values of cell division of control T-cells (Ctr.) or CTPS1-deficient cells (P1.2) ( $n=4$ ). Unpaired t-tests and  $**P<0.01$ . **g**, Representative dot plots of cell cycle progression of control (Ctr.) and CTPS1-deficient T-cells (patient P1.2) stimulated with anti-CD3 antibody. The percentages of cells in each stage are indicated. Data from one of 2 independent experiments. **h**, Proliferation of control (Ctr.) or CTPS1-deficient CD19<sup>+</sup> B cells from PBMCs of healthy donor and patient P1.2. Cells were stimulated with anti-BCR plus CpG during 5 days. The proliferation was analyzed similarly as in (e). Representative data from one of 2 independent experiments.



**Figure 3. CTPS1 is required for proliferation of T-cells in response to TCR-CD3 activation**  
**a**, Proliferation of T-cells in which CTPS1 expression was silenced with vectors containing shRNA for CTPS1 (Sh CTPS1#1 or Sh CTPS1#2) or containing a scramble shRNA (Sh scramble) with GFP gene reporter. Representative dot plots of GFP<sup>+</sup> cells corresponding to transduced cells (left upper panels). Representative histograms of violet dye dilution showing the cell divisions after stimulation (left lower panels). Curves showing the percentage of GFP<sup>+</sup> transduced cells in long-term expansions after repeated stimulation (middle panel). Immunoblots for CTPS1 and CTPS2 expression in transduced cells (right

panels) and ACTIN as loading control. One representative of two experiments. **b,c**, Proliferation of control (Ctr.) and CTPS1-deficient T-cells (patient P1.2) transduced by empty or wild-type *CTPS1*-containing vector. Representative histograms of violet dye dilution (**b**, left panels). Means of indexes of cell division after stimulation (**b**, right panels) from triplicate of one representative of two experiments. Curves showing the percentage of GFP<sup>+</sup> transduced cells same as in (**a**) (**c**, left panel). Representative data from one of 2 independent experiments. Immunoblots same as in (**a**) (**c**, right panels). **d**, Representative histograms of violet dye dilution showing cell divisions of control (Ctr.) and CTPS1-deficient T cells (P1.2) incubated with the indicated nucleotides or nucleosides before stimulation. Data from one of 3 independent experiments. **e**, Incorporation of <sup>14</sup>C-aspartate, a tracer of the *de novo* pyrimidine nucleotide synthesis and <sup>3</sup>H-thymidine as a control of proliferation/DNA synthesis. T cells were labelled during stimulation. Means of incorporated radioactivity (cpm) (*n*=6) **f**, Same as (**d**) excepted that control T-cells were incubated with deazauridine. Data from one representative of 3 independent experiments. **g**, Concentration of CTP in control T-cells incubated with deazauridine (Ctr.+Deaza., *n*=4) or not (Ctr., *n*=6) and CTPS1-deficient cells (P1.2, *n*=3) after stimulation with anti-CD3/CD28 coated beads. Data from 3 independent experiments. **h**, Concentration of CTP in cell extracts of EBV B-cell lines from healthy controls (Ctr.; *n*=6), and CTPS1-deficient patients transduced (Pat.+CTPS1, *n*=4) or not (Pat., *n*=6) with wild-type *CTPS1*-containing vector. P1.1 (squares), P1.2 (circles) and P2.1 (triangles). For controls, each symbol corresponds to cells of a different donor. Data from 2 independent experiments. **i**, Proliferation of CTPS1-deficient EBV B-cell lines (P1.2 and P2.1) transduced by empty or wild-type *CTPS1*-containing vector. Curves showing the percentage of GFP<sup>+</sup>-transduced cells in culture. Unpaired t-tests and \*\*\**P*<0.001, \*\**P*<0.01, \**P*<0.05 (**b**, **e**, **g**, **h**).

**Table 1**

**Clinical features of patients**

Patient	Age at 1 <sup>st</sup> symptoms	Viral infections			Bacterial infections	Extra-hematopoietic manifestations	Outcome (age in years)
		EBV	VZV	Others			
P1.1	1 y.	SIM, chronic viremia	no	CMV, Novovirus, Rotavirus (gut) Parainfluenzae I (RTI)	<i>H. influenzae</i> (RTI)	no	HSCT (8 y.) died (GVHD) (8 y.)
P1.2	1 m.	SIM	no	Adenovirus, HHV-6, Novovirus (gut)	yes, n.k. (RTI)	no	alive (9 y.)
P2.1	5 y.	LPD (CNS)	yes	no	<i>H. influenzae</i> (RTI)	no	HSCT (9 y.) a.w. (17 y.)
P2.2	2 y.	chronic viremia	no	no	<i>S. pneumoniae</i> , <i>H. influenzae</i> (RTI)	no	HSCT (7 y.) a.w. (13 y.)
P3.1	1 y.	n.k.	yes (gastritis, pneumonitis)	no	<i>S. pneumoniae</i> (sepsis, meningitis)	no	died (disseminated VZV) (4 y.)
P3.2	3 m.	SIM, chronic viremia	yes	HHV-6	no	no	HSCT (8 y.) a.w. (12 y.)
P4	birth	LPD (CNS)	yes	CMV, Adenovirus, Rotavirus (gut)	no	no	HSCT (6 y.) died (LPD) (6 y.)
P5	3 m.	LPD (CNS, liver), chronic viremia	no	Novovirus (gut) Parainfluenzae III, Adenovirus, Rhinovirus (RTI)	<i>N. meningitis B</i> (meningitis)	no	HSCT (1 y.) alive (2 y.)

y., year. m., month. SIM, severe infectious mononucleosis. CNS, central nervous system. EBV, Epstein-Barr virus. VZV, varicella zona virus. HHV-6, human herpes virus 6.

LPD, lymphoproliferative disease. RTI, respiratory tract infection. CMV, cytomegalovirus. HSCT, hematopoietic stem cell transplantation. GVHD, graft versus host disease. n.k., not known. a.w., alive and well.